24, 2026 /PRNewswire/ --Today, Novo Nordisk announced that, effective January 1, 2027, the company will lower the list price, or wholesale acquisition cost (WAC), of Wegovy (semaglutide) injection 2.4 mg and tablets 25 mg, Ozempic (semaglutide) injection 0.5 mg, 1 mg, and 2 mg, and Rybelsus (semaglutide) tablets 7 mg or 14 mg to $675, representing reductions of approximately 50% and 35% for Wegovy and Ozempic , respectively, from the current list price
Reduce appetite by acting on the brains satiety centers
Whether or not the benefits of GLP-1s outweigh the risks in the long run varies widely depending on the individual
2002;282(3):G42431
By supporting antioxidant levels, youre giving your body the tools it needs to rest, repair, and regulate sleep cycles more effectively
The combination of significant caloric restriction (from appetite suppression) and no resistance training leads to muscle loss alongside fat loss